Compass Therapeutics (CMPX) Equity Average (2023 - 2026)
Compass Therapeutics' Equity Average history spans 4 years, with the latest figure at $191.6 million for Q1 2026.
- On a quarterly basis, Equity Average rose 62.74% to $191.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $191.6 million, a 62.74% increase, with the full-year FY2025 number at $161.0 million, up 17.63% from a year prior.
- Equity Average hit $191.6 million in Q1 2026 for Compass Therapeutics, down from $203.2 million in the prior quarter.
- Over the last five years, Equity Average for CMPX hit a ceiling of $203.2 million in Q4 2025 and a floor of $101.7 million in Q2 2025.
- Historically, Equity Average has averaged $154.8 million across 4 years, with a median of $152.8 million in 2024.
- Biggest five-year swings in Equity Average: crashed 32.88% in 2025 and later skyrocketed 62.74% in 2026.
- Tracing CMPX's Equity Average over 4 years: stood at $154.3 million in 2023, then fell by 14.57% to $131.8 million in 2024, then skyrocketed by 54.16% to $203.2 million in 2025, then fell by 5.69% to $191.6 million in 2026.
- Business Quant data shows Equity Average for CMPX at $191.6 million in Q1 2026, $203.2 million in Q4 2025, and $151.4 million in Q3 2025.